Summary
This is a Phase II, multi-center, open-label platform study evaluating novel combination
treatment options in participants with locally advanced or metastatic NSCLC. The study
will consist of several sub-studies, each evaluating the safety, tolerability, and
preliminary antitumour activity of various treatment combinations. This study will be
conducted in approximately 80 centers globally across 10 countries.